The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.

A loading dose of MPA employing a regimen of 1,000 mg six hourly for 8 doses can achieve plateau levels above 100 ng ml-1 within the first 36 h of treatment, without any untoward toxicity. This raises the possibility of shortening the time to response for this agent. The additional factor of the tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Canney, P. A., Dowsett, M., Priestman, T. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1988
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246490/
https://www.ncbi.nlm.nih.gov/pubmed/2971386
_version_ 1782150782638882816
author Canney, P. A.
Dowsett, M.
Priestman, T. J.
author_facet Canney, P. A.
Dowsett, M.
Priestman, T. J.
author_sort Canney, P. A.
collection PubMed
description A loading dose of MPA employing a regimen of 1,000 mg six hourly for 8 doses can achieve plateau levels above 100 ng ml-1 within the first 36 h of treatment, without any untoward toxicity. This raises the possibility of shortening the time to response for this agent. The additional factor of the time required to achieve adequate serum levels may explain the apparent contradictions between reports correlating response rates and dose and those correlating serum level and response.
format Text
id pubmed-2246490
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22464902009-09-10 The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast. Canney, P. A. Dowsett, M. Priestman, T. J. Br J Cancer Research Article A loading dose of MPA employing a regimen of 1,000 mg six hourly for 8 doses can achieve plateau levels above 100 ng ml-1 within the first 36 h of treatment, without any untoward toxicity. This raises the possibility of shortening the time to response for this agent. The additional factor of the time required to achieve adequate serum levels may explain the apparent contradictions between reports correlating response rates and dose and those correlating serum level and response. Nature Publishing Group 1988-07 /pmc/articles/PMC2246490/ /pubmed/2971386 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Canney, P. A.
Dowsett, M.
Priestman, T. J.
The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
title The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
title_full The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
title_fullStr The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
title_full_unstemmed The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
title_short The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
title_sort pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246490/
https://www.ncbi.nlm.nih.gov/pubmed/2971386
work_keys_str_mv AT canneypa thepharmacokineticsofmedroxyprogesteroneacetatefollowingtwodifferentloadingdoseschedulesinadvancedcarcinomaofthebreast
AT dowsettm thepharmacokineticsofmedroxyprogesteroneacetatefollowingtwodifferentloadingdoseschedulesinadvancedcarcinomaofthebreast
AT priestmantj thepharmacokineticsofmedroxyprogesteroneacetatefollowingtwodifferentloadingdoseschedulesinadvancedcarcinomaofthebreast
AT canneypa pharmacokineticsofmedroxyprogesteroneacetatefollowingtwodifferentloadingdoseschedulesinadvancedcarcinomaofthebreast
AT dowsettm pharmacokineticsofmedroxyprogesteroneacetatefollowingtwodifferentloadingdoseschedulesinadvancedcarcinomaofthebreast
AT priestmantj pharmacokineticsofmedroxyprogesteroneacetatefollowingtwodifferentloadingdoseschedulesinadvancedcarcinomaofthebreast

Ejemplares similares